Patients
primary systemic amyloidosis
AL
poor prognosis
Median survival time
standard
treatments
months
High-dose
intravenous
peripheral blood stem cell transplant
PBSCT
therapy
treatment mortality
authors
development
acute renal insufficiency
melphalan
conditioning
study
risk factors
impact
posttransplant
mortality
